Protein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
Int J Mol Sci. 2021 Feb 18;22(4):2008. doi: 10.3390/ijms22042008.
Around 77 new oncology drugs were approved by the FDA in the past five years; however, most cancers remain untreated. Small molecules and antibodies are dominant therapeutic modalities in oncology. Antibody-drug conjugates, bispecific antibodies, peptides, cell, and gene-therapies are emerging to address the unmet patient need. Advancement in the discovery and development platforms, identification of novel targets, and emergence of new technologies have greatly expanded the treatment options for patients. Here, we provide an overview of various therapeutic modalities and the current treatment options in oncology, and an in-depth discussion of the therapeutics in the preclinical stage for the treatment of breast cancer, lung cancer, and multiple myeloma.
在过去五年中，FDA 批准了大约 77 种新的肿瘤药物；然而，大多数癌症仍然无法治疗。小分子和抗体是肿瘤学中的主要治疗方式。抗体药物偶联物、双特异性抗体、肽、细胞和基因疗法的出现是为了满足未满足的患者需求。发现和开发平台的进步、新靶标的鉴定以及新技术的出现极大地扩展了患者的治疗选择。在这里，我们提供了各种治疗方式的概述和肿瘤学中的当前治疗选择，并深入讨论了治疗乳腺癌、肺癌和多发性骨髓瘤的临床前阶段的治疗方法。
